Kioxia Holdings Corp shelved plans to list on the Tokyo Stock Exchange on Oct. 6 and offer up to $3.2 billion in shares due to tighter US restrictions on Huawei Technologies Co Ltd that could result in oversupply and lower prices of memory chips.
The initial public offering (IPO) would have been Japan’s biggest this year.
Kioxia, previously known as Toshiba Memory, made no mention of the curbs and only cited market volatility and ng concerns about a second wave of the pandemic in putting off the IPO.
Shares in top shareholder Toshiba Corp, which had planned to sell an 8 percent stake, dropped by as much as 8.6 percent due to the postponement, before paring the losses to 3 percent.
The memory chip market is bracing for the impact of the US restriction on global suppliers from selling US technology-based chips to Huawei without a special license that came into force on Sept. 15.
Kioxia CEO Nobuo Hayasaka said that while the company received significant interest from investors, they do not believe it is the best time to proceed with the IPO, and they are not in a rush.
Earlier this month, Kioxia set a tentative IPO price range that put the market value lower than $18.9 billion.
The consortium’s stake was to drop from 56.2 percent to 47.8 percent.


Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



